---
title: "Novo Nordisk completely dismantles the diabetes cell therapy department"
description: "Danish pharmaceutical company Novo Nordisk announced on Friday the closure of its cell therapy department, which is responsible for drug development for Type 1 diabetes. The company stated in a statem"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260680169.md"
published_at: "2025-10-10T18:33:29.000Z"
---

# Novo Nordisk completely dismantles the diabetes cell therapy department

> Danish pharmaceutical company Novo Nordisk announced on Friday the closure of its cell therapy department, which is responsible for drug development for Type 1 diabetes. The company stated in a statement that it is seeking partners to continue advancing related research. According to reports from《Borsen》, nearly all of the approximately 250 employees in that department were laid off, and Novo Nordisk did not disclose further specific details

Danish pharmaceutical company Novo Nordisk (NVO.US) announced on Friday the closure of its cell therapy department, which was responsible for drug development for Type 1 diabetes.

The company stated in a statement that it is seeking partners to continue advancing related research. According to reports from Borsen, nearly all of the approximately 250 employees in that department were laid off, and Novo Nordisk did not disclose further specific details

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德公司提议任命两名新的董事会成员 | 丹麦制药公司诺和诺德公司提议在 3 月 26 日于哥本哈根举行的年度股东大会上新增三名董事会成员。提议的成员包括海伦娜·萨克森、扬·范·德·温克尔和拉莫娜·塞奎拉。萨克森此前已宣布辞去 Sobi 的职务以加入诺和诺德。还提议重新选举董事长拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| 诺和诺德公司：将在 Ozempic 和 Wegovy 专利到期时准备好替代产品 - Berlingske | 丹麦制药公司诺和诺德计划在其药物 Ozempic 和 Wegovy 的专利于 2031 年在欧洲和 2032 年在美国到期时，准备好替代药物。研究负责人马丁·霍尔斯特·朗格表示，某些临床试验中的候选药物可能会在 2030 年前提交审批。有关 | [Link](https://longbridge.com/en/news/276314777.md) |
| Madrigal 制药｜8-K：2025 财年 Q4 营收 3.21 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276330350.md) |
| 诺和诺德公司 - 股份回购计划 | 诺和诺德公司已启动一项最高达 150 亿丹麦克朗的股票回购计划，计划于 2026 年 2 月 4 日开始。截至 2026 年 2 月 13 日，公司已回购 1,750,000 股 B 类股票，平均价格为 305.03 丹麦克朗，总计为 53 | [Link](https://longbridge.com/en/news/276056741.md) |
| 高盛：诺和诺德定价压力被市场过度定价，口服 Wegovy 将是扭转信心的关键 | 高盛称，当前股价已完全消化 2026 财年最悲观预期。市场低估了 Medicare 放开的销量潜力和口服版 Wegovy 的收入前景。口服 Wegovy 上市表现强劲，已开出 5 万张处方，其中 9 成为自费需求，显示刚性市场潜力，将成为扭 | [Link](https://longbridge.com/en/news/275095024.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
